Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/194262
Title: | Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenstrom macroglobulinaemia |
Author: | Moreno, David F. López-Guerra, Mónica Paz, Sara Oliver Caldés, Aina Mena, Mari-Pau Correa, Juan Carlos Battram, Anthony M. Osuna, Miguel Rivas Delgado, Alfredo Rodríguez Lobato, Luis Gerardo Cardús, Oriol Tovar, Natalia Cibeira, María Teresa Jiménez, Raquel Bladé, J. (Joan) Rosiñol, Laura Colomer Pujol, Dolors Fernández de Larrea Rodríguez, Carlos José |
Keywords: | Mutació (Biologia) Reacció en cadena de la polimerasa Impacte Mutation (Biology) Polymerase chain reaction Impact |
Issue Date: | 9-Oct-2022 |
Publisher: | John Wiley & Sons |
Abstract: | Waldenstrom macroglobulinaemia (WM) is characterized by recurrent somatic mutations in MYD88 and CXCR4 genes. However, limitations arise when analysing these mutations in IgM monoclonal gammopathy of undetermined significance (MGUS) or smouldering WM (SWM) given the lower tumour load. Here, we used droplet digital polymerase chain reaction (ddPCR) to analyse MYD88 L265P and CXCR4 S338* mutations (C1013G and C1013A) in unsorted bone marrow (BM) or cell-free DNA (cfDNA) samples from 101 IgM MGUS and 69 SWM patients. ddPCR was more sensitive to assess MYD88 L265P compared to allele-specific PCR, especially in IgM MGUS (64% vs 39%). MYD88 mutation burden correlated with other laboratory biomarkers, particularly BM infiltration (r = 0.8; p < 0.001). CXCR4 C1013G was analysed in MYD88-mutated samples with available genomic DNA and was detected in 19/54 (35%) and 18/42 (43%) IgM MGUS and SWM cases respectively, also showing correlation with BM involvement (r = 0.9; p < 0.001). ddPCR also detected 8 (38%) and 10 (63%) MYD88-mutated cfDNA samples in IgM MGUS and SWM respectively. Moreover, high BM mutation burden (>= 8% MYD88 and >= 2% CXCR4) was associated with an increased risk of progression to symptomatic WM. We show the clinical applicability of ddPCR to assess MYD88 and CXCR4 in IgM MGUS and SWM and provide a molecular-based risk classification. |
Note: | Reproducció del document publicat a: https://doi.org/10.1111/bjh.18502 |
It is part of: | British Journal of Haematology, 2022, vol. 200, num. 2, p. 187-196 |
URI: | http://hdl.handle.net/2445/194262 |
Related resource: | https://doi.org/10.1111/bjh.18502 |
ISSN: | 0007-1048 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
730803.pdf | 5.12 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License